FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

November 18, 2020

Press Releases

Comments Off on FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

A significant increase in mortality has been seen in COVID-19 patients with antibiotic resistant bacterial infections. APT has made available therapeutic phage treatment to physicians in the Rio Grande Valley of Texas who are treating COVID-19 patients with secondary Carbapenem Resistant Acinetobacter baumannii (CRAB) on an emergency basis Now the FDA has granted APT an Expanded […]

PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients

November 2, 2020

Press Releases

Comments Off on PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients

November 02, 2020 11:00 AM Eastern Standard Time Eight COVID-19 + CRAB patients have received PhageBank™ therapy under FDA-approved emergency allowance, with more anticipated Significant increased mortality has been observed from secondary CRAB infections in COVID-19 patients APT and its partners are currently self-funding emergency use of PhageBank™ in this patient group, and are seeking […]

Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections

October 22, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections

October 22, 2020 11:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of multi-drug resistant infectious diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections […]

Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine

August 20, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine

August 20, 2020 11:09 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus […]

Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing

August 5, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing

— Proceeds to fund clinical trial for PhageBank treatment in periprosthetic joint infections — August 05, 2020 09:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed […]

Adaptive Phage Therapeutics Enters Agreement with Mayo Clinic to Commercialize a Phage Susceptibility Test

June 9, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Enters Agreement with Mayo Clinic to Commercialize a Phage Susceptibility Test

— Assay to rapidly match therapeutic phage to antibiotic-resistant infections — June 09, 2020 09:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a […]

FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections

March 12, 2020

Press Releases

Comments Off on FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections

— Three Clinical Sites to Enroll Patients with Recurrent and Complicated Urinary Tract Infections — March 12, 2020 10:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the U.S. Food and […]

Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program

February 10, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program

–Company is Recognized Top 1% among 4,000 applicants from 133 Countries– February 10, 2020 10:00 AM Eastern Standard Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the company has been selected to participate […]

Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense

January 8, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense

Funds Designated to Support Clinical Development of PhageBankTM Precision Bacteriophage Therapeutic January 08, 2020 10:00 AM Eastern Standard Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced the Department of Defense (DoD) has awarded APT a contract of […]

Adaptive Phage Therapeutics to Present to Investors at 2019 World Antimicrobial Resistance Congress

October 30, 2019

Press Releases

Comments Off on Adaptive Phage Therapeutics to Present to Investors at 2019 World Antimicrobial Resistance Congress

–CEO to Outline Vision at Global Gathering of Infectious Disease Leaders and Investors– October 30, 2019 08:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that Greg Merril, CEO and co-founder […]